← Leaderboards

Bharat Ramratnam

Aaron Diamond Aids Research Center

Google Scholar ↗PubMed ↗ORCID ↗

$19,358,041

Attributed

$22,881,010

Total exposure

24

Grants

20

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3M · FY2005–23

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

Funding mix

By agency

NIH$34,645,942 · 27

By mechanism

P30$8,808,753 · 4

P20$8,087,710 · 7

R01$7,894,380 · 3

U19$4,866,534 · 3

U54$1,394,178 · 1

P01$1,202,687 · 2

Top collaborators

Others in their field

Top investigators on “Research Personnel”

David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
Sonia M Thomas · Research Triangle Institute$700,865,642
Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
Tracy L Nolen · Research Triangle Institute$474,487,152
David R. Weir · University Of Michigan At Ann Arbor$364,053,504
Judith S. Currier · University Of California Los Angeles$284,675,012

Research focus

Research PersonnelFundingHiv-1United States National Institutes Of HealthClinical ResearchServicesResourcesBaseProteinsInfectionBasic ScienceSamplingUniversitiesViralLongevityTissuesGrantWomanMacrophageProgramsMediatingMacacaProteomicsTransmission Process

Grant awards (89)

Next-generation extracellular vesicle biologics to target central nervous system and peripheral reservoirs of HIV$770,678

R01 · FY2023 · AI

Next-generation extracellular vesicle biologics to target central nervous system and peripheral reservoirs of HIV$786,419

R01 · FY2022 · AI

Next-generation extracellular vesicle biologics to target central nervous system and peripheral reservoirs of HIV$796,244

R01 · FY2021 · AI

Next-generation extracellular vesicle biologics to target central nervous system and peripheral reservoirs of HIV$805,578

R01 · FY2020 · AI

Clinical Research Resources and Facilities$281,686

U54 · FY2020 · GM · contact PI

COBRE Center for Cancer Research Development$1,137,315

P30 · FY2019 · GM · contact PI

Next-generation extracellular vesicle biologics to target central nervous system and peripheral reservoirs of HIV$830,593

R01 · FY2019 · AI

Clinical Research Resources and Facilities$281,687

U54 · FY2019 · GM · contact PI

COBRE Center for Cancer Research Development$223,418

P30 · FY2019 · GM · contact PI

Virology Core$143,632

P01 · FY2019 · AA · contact PI

COBRE Center for Cancer Research Development$1,154,147

P30 · FY2018 · GM · contact PI

COBRE Center for Cancer Research Development$292,526

P30 · FY2018 · GM · contact PI

Clinical Research Resources and Facilities$234,954

U54 · FY2018 · GM · contact PI

Studies in HIV-1 Pathogenesis and Transmission$161,487

K24 · FY2018 · HD · contact PI

Virology Core$130,703

P01 · FY2018 · AA · contact PI

COBRE Center for Cancer Research Development$1,166,293

P30 · FY2017 · GM · contact PI

Clinical Research Resources and Facilities$311,999

U54 · FY2017 · GM · contact PI

COBRE Center for Cancer Research Development$277,856

P30 · FY2017 · GM · contact PI

Studies in HIV-1 Pathogenesis and Transmission$161,487

K24 · FY2017 · HD · contact PI

Retrovirology$92,106

P30 · FY2017 · AI · contact PI

Virology Core$76,828

P01 · FY2017 · AA · contact PI

COBRE Center for Cancer Research Development$1,181,126

P30 · FY2016 · GM · contact PI

Reproductive Hormones and their impact on HIV-1 acquisition$438,033

R01 · FY2016 · HD · contact PI

COBRE Center for Cancer Research Development$428,090

P30 · FY2016 · GM · contact PI

Clinical Research Resources and Facilities$283,852

U54 · FY2016 · GM · contact PI

COBRE Center for Cancer Research Development$263,637

P30 · FY2016 · GM · contact PI

Retrovirology$190,619

P30 · FY2016 · AI · contact PI

Studies in HIV-1 Pathogenesis and Transmission$161,487

K24 · FY2016 · HD · contact PI

Virology Core$76,773

P01 · FY2016 · AA · contact PI

COBRE Center for Cancer Research Development$1,213,463

P30 · FY2015 · GM · contact PI

Reproductive Hormones and their impact on HIV-1 acquisition$440,037

R01 · FY2015 · HD · contact PI

COBRE Center for Cancer Research Development$260,386

P30 · FY2015 · GM · contact PI

Studies in HIV-1 Pathogenesis and Transmission$161,487

K24 · FY2015 · HD · contact PI

Retrovirology$138,099

P30 · FY2015 · AI · contact PI

Virology Core$84,293

P01 · FY2015 · AA · contact PI

Reproductive Hormones and their impact on HIV-1 acquisition$447,131

R01 · FY2014 · HD · contact PI

Studies in HIV-1 Pathogenesis and Transmission$161,487

K24 · FY2014 · HD · contact PI

Virology Core$123,303

P01 · FY2014 · AA · contact PI

COBRE Center for Cancer Research Development$2,193,066

P20 · FY2013 · GM · contact PI

Reproductive Hormones and their impact on HIV-1 acquisition$451,456

R01 · FY2013 · HD · contact PI

Virology Core$143,013

P01 · FY2013 · AA · contact PI

COBRE Center for Cancer Research Development$2,260,550

P20 · FY2012 · GM · contact PI

Reproductive Hormones and their impact on HIV-1 acquisition$515,662

R01 · FY2012 · HD · contact PI

Virology Core$127,119

P01 · FY2012 · AA · contact PI

COBRE Center for Cancer Research Development$2,251,971

P20 · FY2011 · RR · contact PI

MOLECULAR CORE$331,431

P20 · FY2011 · RR · contact PI

Retrovirology Services$132,529

P30 · FY2011 · AI · contact PI

Virology Core$127,120

P01 · FY2011 · AA · contact PI

MOLECULAR CORE$326,332

P20 · FY2010 · RR · contact PI

Retrovirology Services$199,634

P30 · FY2010 · AI · contact PI

Virology Core$169,903

P01 · FY2010 · AA · contact PI

siRNA Microbicides$742,229

U19 · FY2009 · AI · contact PI

Overcoming HIV-1 resistance to RNA Interference$347,418

R01 · FY2009 · AI · contact PI

Novel Si RNA microbicides to prevent HIV-1 infection$176,230

U19 · FY2009 · AI · contact PI

Retrovirology Services$131,047

P30 · FY2009 · AI · contact PI

siRNA Microbicides$923,680

U19 · FY2008 · AI · contact PI

Overcoming HIV-1 resistance to RNA Interference$347,418

R01 · FY2008 · AI · contact PI

CV-N AS A MICROBICIDE$226,032

U19 · FY2008 · AI · contact PI

Retrovirology Services$186,233

P30 · FY2008 · AI · contact PI

Novel Si RNA microbicides to prevent HIV-1 infection$176,414

U19 · FY2008 · AI · contact PI

siRNA Microbicides$716,617

U19 · FY2007 · AI · contact PI

Overcoming HIV-1 resistance to RNA Interference$354,147

R01 · FY2007 · AI · contact PI

CV-N AS A MICROBICIDE$235,157

U19 · FY2007 · AI · contact PI

SIRNA MICROBICIDES$190,553

P51 · FY2007 · RR · contact PI

NOVEL HIV-1 MICROBICIDES$190,552

P51 · FY2007 · RR · contact PI

Novel Si RNA microbicides to prevent HIV-1 infection$156,604

U19 · FY2007 · AI · contact PI

Retrovirology Services$140,229

P30 · FY2007 · AI · contact PI

P3: RNA INTERFERENCE TO DISSECT STEM CELL POTENTIAL$60,308

P20 · FY2007 · RR · contact PI

siRNA Microbicides$850,001

U19 · FY2006 · AI · contact PI

Overcoming HIV-1 resistance to RNA Interference$364,724

R01 · FY2006 · AI · contact PI

Novel HIV-1 Microbicides$238,267

R21 · FY2006 · AI · contact PI

CV-N AS A MICROBICIDE$236,023

U19 · FY2006 · AI · contact PI

Novel Si RNA microbicides to prevent HIV-1 infectio$181,759

U19 · FY2006 · AI · contact PI

COBRE: RW HOSP: P3: RNA INTERFERENCE TO DISSECT STEM CELL POTENTIAL$178,952

P20 · FY2006 · RR · contact PI

NOVEL HIV-1 MICROBICIDES$134,807

P51 · FY2006 · RR · contact PI

CV-N AS A MICROBICIDE$245,788

U19 · FY2005 · AI

Novel HIV-1 Microbicides$218,825

R21 · FY2005 · AI

Overcoming HIV-1 resistance to RNA Interference$198,842

R01 · FY2005 · AI

COBRE: RW HOSP: P3: RNA INTERFERENCE TO DISSECT STEM CELL POTENTIAL$183,473

P20 · FY2005 · RR

RNA INTERFERENCE TO DISSECT STEM CELL POTENTIAL$301,627

P20 · FY2004 · RR

NOVEL APPROACHES TO TARGET LATENT RESERVOIRS OF HIV-1$122,256

K23 · FY2004 · AI

NOVEL APPROACHES TO TARGET LATENT RESERVOIRS OF HIV-1$122,256

K23 · FY2003 · AI

NOVEL APPROACHES TO TARGET LATENT RESERVOIRS OF HIV-1$122,256

K23 · FY2002 · AI

LYMPHOCYTE TURNOVER IN HEALTHY VOLUNTEERS &HIV 1 INFECTED PATIENTS$0

M01 · FY2002 · RR

NOVEL APPROACHES TO TARGET LATENT RESERVOIRS OF HIV-1$75,954

K23 · FY2001 · AI

NOVEL APPROACHES TO TARGET LATENT RESERVOIRS OF HIV-1$48,842

K23 · FY2001 · AI

LYMPHOCYTE TURNOVER IN HEALTHY VOLUNTEERS &HIV 1 INFECTED PATIENTS$0

M01 · FY2001 · RR

NOVEL APPROACHES TO TARGET LATENT RESERVOIRS OF HIV-1$119,697

K23 · FY2000 · AI

LYMPHOCYTE TURNOVER IN HEALTHY VOLUNTEERS &HIV 1 INFECTED PATIENTS$0

M01 · FY2000 · RR